Supernus Pharmaceuticals Inc (NAS:SUPN)

$ 37.035 -0.715 (-1.89%) Market Cap: 2.05 Bil Enterprise Value: 1.71 Bil PE Ratio: 34.64 PB Ratio: 2.03 GF Score: 83/100

Q3 2024 Supernus Pharmaceuticals Inc Earnings Call Transcript
3 days ago

$34.7 (+2.15%)

Earnings
Q2 2024 Supernus Pharmaceuticals Inc Earnings Call Transcript
Aug 06, 2024

$27.88 (-0.14%)

Earnings
Q1 2024 Supernus Pharmaceuticals Inc Earnings Call Transcript
May 08, 2024

$31.3 (+0.48%)

Earnings
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call Transcript
Feb 27, 2024

$30.69 (+4.03%)

Earnings
Q3 2023 Supernus Pharmaceuticals Inc Earnings Call Transcript
Nov 08, 2023

$23.52 (-1.42%)

Earnings
Supernus Pharmaceuticals Inc R&D Day Transcript
Oct 18, 2023
Q2 2023 Supernus Pharmaceuticals Inc Earnings Call Transcript
Aug 08, 2023

$32.91 (+2.05%)

Earnings
Supernus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Q1 2023 Supernus Pharmaceuticals Inc Earnings Call Transcript
May 09, 2023

$36.18 (-1.66%)

Earnings
Q4 2022 Supernus Pharmaceuticals Inc Earnings Call Transcript
Feb 28, 2023

$37.59 (-0.97%)

Earnings
Q3 2022 Supernus Pharmaceuticals Inc Earnings Call Transcript
Nov 08, 2022

$34.7 (-0.06%)

Earnings
Q2 2022 Supernus Pharmaceuticals Inc Earnings Call Transcript
Aug 04, 2022

$32.81 (+2.47%)

Earnings
Q1 2022 Supernus Pharmaceuticals Inc Earnings Call Transcript
May 09, 2022

$26.37 (-4.04%)

Earnings
Preliminary Q4 2021 Supernus Pharmaceuticals Inc Earnings Call Transcript
Feb 28, 2022

$31.95 (+3.16%)

Earnings
Q3 2021 Supernus Pharmaceuticals Inc Earnings Call Transcript
Nov 03, 2021

$30.03 (-0.10%)

Earnings
Supernus Pharmaceuticals Inc Acquisition of Adamas Pharmaceuticals Inc - M&A Call Transcript
Oct 11, 2021
Supernus Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 15, 2021
Q2 2021 Supernus Pharmaceuticals Inc Earnings Call Transcript
Aug 04, 2021

$27.18 (+1.08%)

Earnings
Q1 2021 Supernus Pharmaceuticals Inc Earnings Call Transcript
May 05, 2021

$30.49 (+1.30%)

Earnings
Supernus Pharmaceuticals Inc at Cowen Healthcare Conference (Virtual) Transcript
Mar 03, 2021
Q4 2020 Supernus Pharmaceuticals Inc Earnings Call Transcript
Feb 25, 2021

$29.45 (-4.82%)

Earnings
Supernus Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 14, 2021
Q3 2020 Supernus Pharmaceuticals Inc Earnings Call Transcript
Nov 04, 2020

$22.47 (+23.80%)

Earnings
Supernus Pharmaceuticals Inc at Morgan Stanley Global Healthcare Conference (Virtual) Transcript
Sep 16, 2020
Q2 2020 Supernus Pharmaceuticals Inc Earnings Call Transcript
Aug 19, 2020

$23.4 (-6.59%)

Earnings
Q1 2020 Supernus Pharmaceuticals Inc Earnings Call Transcript
May 06, 2020

$23.17 (+4.51%)

Earnings
Supernus Pharmaceuticals Inc to Acquire the CNS portfolio of Us WorldMeds LLC - Conference Call Transcript
Apr 29, 2020
Q4 2019 Supernus Pharmaceuticals Inc Earnings Call Transcript
Feb 26, 2020

$19.52 (-14.91%)

Earnings
Supernus Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Q3 2019 Supernus Pharmaceuticals Inc Earnings Call Transcript
Nov 06, 2019

$19.93 (-31.58%)

Earnings
Supernus Pharmaceuticals Inc at Morgan Stanley Healthcare Conference Transcript
Sep 11, 2019
Q2 2019 Supernus Pharmaceuticals Inc Earnings Call Transcript
Aug 07, 2019

$28.31 (-14.98%)

Earnings
Q1 2019 Supernus Pharmaceuticals Inc Earnings Call Transcript
May 08, 2019

$35.66 (-3.52%)

Earnings
Supernus Pharmaceuticals Inc Investor Day Transcript
Apr 16, 2019
Supernus Pharmaceuticals Inc to Discuss the SPN-812 Phase III Topline Results - Conference Call Transcript
Mar 28, 2019
Supernus Pharmaceuticals Inc at Cowen Health Care Conference Transcript
Mar 13, 2019
Q4 2018 Supernus Pharmaceuticals Inc Earnings Call Transcript
Feb 27, 2019

$41.99 (+13.86%)

Earnings

Q4 2023 Supernus Pharmaceuticals Inc Earnings Call Transcript

Feb 27, 2024 / 09:30PM GMT

Release Date Price: $30.69 (+4.03%)

Transcript 8-K10-K

Operator

Good afternoon and welcome to the Supernus Pharmaceuticals fourth quarter and full year 2023 financial results conference call. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the conference over to Peter Vozzo of ICR Westwicke, Investor Relations representative for Supernus Pharmaceuticals. You may begin.

Peter Vozzo ICR Westwicke;IR

Thank you, Rivka. Good afternoon, everyone, and thank you for joining us today for Supernus Pharmaceuticals' fourth quarter and full year 2023 financial results conference call. Today after the close of the market, the company issued a press release announcing these results on the call with me today are apprentices, Chief Executive Officer, Jack Khattar; and Chief Financial Officer, Tim Dec.

Today's call is being made available via the Investor Relations section of the company's website at ir.supernus.com. During the course of this call, management may make certain forward-looking statements regarding future events and the company's future

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.